Results 1 to 10 of about 14,910,189 (242)

CAR T cell therapy [PDF]

Immunological Medicine, 2021
Chimeric antigen receptor (CAR) is generated by fusing a cancer-specific antibody’s antigen recognition site with costimulatory molecules such as CD28 and CD3ζ. T cells transduced with CAR recognizes cancer-specific antigens and kill cancer cells.
Naoki Hosen
doaj   +5 more sources

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

Journal of Experimental & Clinical Cancer Research, 2022
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made tremendous progress with five CAR T therapies approved by the US Food and Drug Administration for hematological malignancies.
Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu, Huihong Xu, Chong-xian Pan, Zheng Zhu   +5 more
doaj   +2 more sources

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells

Frontiers in Immunology, 2023
Chimeric antigen receptors (CARs) in the canonical “second generation” format provide two signals for inducing T cell effector functions; the primary “signal-1” is provided through the TCR CD3ζ chain and the “signal-2” through a linked costimulatory ...
Simone Thomas, Simone Thomas, Hinrich Abken, Hinrich Abken   +3 more
doaj   +4 more sources

How CAR T Cells Breathe

Cells, 2022
The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism.
Christopher Forcados, Sandy Joaquina, Nicholas Paul Casey, Benjamin Caulier, Sébastien Wälchli   +4 more
doaj   +4 more sources

CAR T-CELL

Hematology, Transfusion and Cell Therapy, 2021
Francesco Saglio
doaj   +2 more sources

Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy. [PDF]

N Engl J Med
Aleman A, Van Oekelen O, Melnekoff DT, Grossman L, Mouhieddine TH, Kurowski A, Odak I, Reci S, Desai S, Meledathu S, Naidu MP, Shukla RP, Dutta RP, Kappes K, Serebryakova K, Jackson H, Lu J, Chatikhine A, Kulkarni R, Moinfar Z, Croken MM, Mehrotra M, Baskovich B, Rayamajhi S, Richard S, Rossi AC, Salib C, Houldsworth J, Brown BD, Merad M, Laganà A, Brunner PM, Jagannath S, Brody JD, Parekh S.   +34 more
europepmc   +3 more sources

CAR-T cell therapy: current limitations and potential strategies

Blood Cancer Journal, 2021
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit ...
Robert C. Sterner, Rosalie M. Sterner
semanticscholar   +1 more source

Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions

Cells, 2023
T cells expressing chimeric antigen receptors (CARs) are at the forefront of clinical treatment of cancers. Still, the nanoscale organization of CARs at the interface of CAR-Ts with target cells, which is essential for TCR-mediated T cell activation ...
Julia Sajman, Oren Yakovian, Naamit Unger Deshet, Shaked Almog, Galit Horn, Tova Waks, Anat Globerson Levin, Eilon Sherman   +7 more
doaj   +1 more source

Comparing Intraperitoneal and Intravenous Personalized ErbB2CAR-T for the Treatment of Epithelial Ovarian Cancer

Biomedicines, 2022
High-grade serous ovarian carcinoma (HGSOC) is the most common type of epithelial ovarian cancer. The majority of cases are diagnosed at advanced stages, when intraperitoneal (IP) spread has already occurred.
Naamit Deshet-Unger, Galit Horn, Moran Rawet-Slobodkin, Tova Waks, Ido Laskov, Nadav Michaan, Yael Raz, Vered Bar, Adi Zundelevich, Sara Aharon, Lubov Turovsky, Giuseppe Mallel, Seth Salpeter, Guy Neev, Kenneth Samuel Hollander, Ben-Zion Katz, Dan Grisaru, Anat Globerson Levin   +17 more
doaj   +1 more source

Search, identification, and curation of cell and gene therapy product regulations using augmented intelligent systems

Frontiers in Medicine, 2023
BackgroundManually keeping up-to-date with regulations such as directives, guidance, laws, and ordinances related to cell and gene therapy is a labor-intensive process. We used machine learning (ML) algorithms to create an augmented intelligent system to
William Schaut, Akash Shrivastav, Srikanth Ramakrishnan, Robert Bowden   +3 more
doaj   +1 more source